Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2682

1.

Polymorphisms in folic acid metabolism genes do not associate with cancer cachexia in Japanese gastrointestinal patients.

Morishita T, Hishida A, Okugawa Y, Morimoto Y, Shirai Y, Okamoto K, Momokita S, Ogawa A, Tanaka K, Nishikawa R, Toiyama Y, Inoue Y, Sakurai H, Urata H, Tanaka M, Miki C.

Nagoya J Med Sci. 2018 Nov;80(4):529-539. doi: 10.18999/nagjms.80.4.529.

2.

New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia.

Penna F, Costelli P.

Expert Opin Investig Drugs. 2019 Feb;28(2):179-189. doi: 10.1080/13543784.2019.1557634. Epub 2018 Dec 14. Review.

PMID:
30526137
3.

Myokines as Possible Therapeutic Targets in Cancer Cachexia.

Manole E, Ceafalan LC, Popescu BO, Dumitru C, Bastian AE.

J Immunol Res. 2018 Oct 22;2018:8260742. doi: 10.1155/2018/8260742. eCollection 2018. Review.

4.

Progressive resistance training in cachectic head and neck cancer patients undergoing radiotherapy: a randomized controlled pilot feasibility trial.

Grote M, Maihöfer C, Weigl M, Davies-Knorr P, Belka C.

Radiat Oncol. 2018 Nov 6;13(1):215. doi: 10.1186/s13014-018-1157-0.

5.

Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.

Currow DC, Maddocks M, Cella D, Muscaritoli M.

Int J Mol Sci. 2018 Nov 5;19(11). pii: E3471. doi: 10.3390/ijms19113471. Review.

6.

Clinical impact of cachexia in unresectable locally advanced head and neck cancer: supplementary analysis of a phase II trial (JCOG0706-S2).

Matsuzuka T, Kiyota N, Mizusawa J, Akimoto T, Fujii M, Hasegawa Y, Iwae S, Monden N, Matsuura K, Onozawa Y, Hayashi R, Tahara M; Japan Clinical Oncology Group(JCOG) Head and Neck Cancer Study Group.

Jpn J Clin Oncol. 2019 Jan 1;49(1):37-41. doi: 10.1093/jjco/hyy145.

PMID:
30364985
7.

Cancer cachexia and myopenia - Update on management strategies and the direction of future research for optimizing body composition in cancer - A narrative review.

Pring ET, Malietzis G, Kennedy RH, Athanasiou T, Jenkins JT.

Cancer Treat Rev. 2018 Nov;70:245-254. doi: 10.1016/j.ctrv.2018.10.002. Epub 2018 Oct 6. Review.

PMID:
30321741
8.

The Palliative Radiotherapy and Inflammation Study (PRAIS) - protocol for a longitudinal observational multicenter study on patients with cancer induced bone pain.

Habberstad R, Frøseth TCS, Aass N, Abramova T, Baas T, Mørkeset ST, Caraceni A, Laird B, Boland JW, Rossi R, Garcia-Alonso E, Stensheim H, Loge JH, Hjermstad MJ, Bjerkeset E, Bye A, Lund JÅ, Solheim TS, Vagnildhaug OM, Brunelli C, Damås JK, Mollnes TE, Kaasa S, Klepstad P.

BMC Palliat Care. 2018 Sep 28;17(1):110. doi: 10.1186/s12904-018-0362-9.

9.

Myostatin knockout induces apoptosis in human cervical cancer cells via elevated reactive oxygen species generation.

Han YQ, Ming SL, Wu HT, Zeng L, Ba G, Li J, Lu WF, Han J, Du QJ, Sun MM, Yang GY, Wang J, Chu BB.

Redox Biol. 2018 Oct;19:412-428. doi: 10.1016/j.redox.2018.09.009. Epub 2018 Sep 13.

10.

Case 3/2018 - A 60-year-old Female with Chagasic Heart Disease, Admitted Due to Heart Failure Decompensation, Cachexia and Pulmonary Infection.

Arduine GA, Aiello VD.

Arq Bras Cardiol. 2018 Jun;110(6):588-596. doi: 10.5935/abc.20180100. English, Portuguese. No abstract available.

11.

Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention.

Moreira-Pais A, Ferreira R, Gil da Costa R.

Life Sci. 2018 Sep 1;208:1-9. doi: 10.1016/j.lfs.2018.07.010. Epub 2018 Jul 6. Review.

PMID:
30146014
12.

Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models.

Henderson SE, Makhijani N, Mace TA.

Pancreas. 2018 Sep;47(8):937-945. doi: 10.1097/MPA.0000000000001124. Review.

PMID:
30113428
13.

Ghrelin as a Promising Therapeutic Option for Cancer Cachexia.

Khatib MN, Gaidhane A, Gaidhane S, Quazi ZS.

Cell Physiol Biochem. 2018;48(5):2172-2188. doi: 10.1159/000492559. Epub 2018 Aug 15. Review.

14.

Adropin and Irisin in Patients with Cardiac Cachexia.

Mansur AJ.

Arq Bras Cardiol. 2018 Jul;111(1):48-49. doi: 10.5935/abc.20180121. English, Portuguese. No abstract available.

15.

The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews.

Zhang F, Shen A, Jin Y, Qiang W.

BMC Complement Altern Med. 2018 Aug 9;18(1):236. doi: 10.1186/s12906-018-2304-8. Review.

16.

mTOR and Tumor Cachexia.

Duval AP, Jeanneret C, Santoro T, Dormond O.

Int J Mol Sci. 2018 Jul 30;19(8). pii: E2225. doi: 10.3390/ijms19082225. Review.

17.

Quality assessment of cancer cachexia clinical practice guidelines.

Shen WQ, Yao L, Wang XQ, Hu Y, Bian ZX.

Cancer Treat Rev. 2018 Nov;70:9-15. doi: 10.1016/j.ctrv.2018.07.008. Epub 2018 Jul 18. Review.

PMID:
30053727
18.

Resistance Exercise's Ability to Reverse Cancer-Induced Anabolic Resistance.

Montalvo RN, Hardee JP, VanderVeen BN, Carson JA.

Exerc Sport Sci Rev. 2018 Oct;46(4):247-253. doi: 10.1249/JES.0000000000000159. Review.

PMID:
30001273
19.

Cachexia in hospitalized patients with heart failure.

Santos NFD, Pinho CPS, Cardoso AJPF, Mendes RML.

Nutr Hosp. 2018 Apr 27;35(3):669-676. doi: 10.20960/nh.1390.

20.

Adropin and Irisin in Patients with Cardiac Cachexia.

Kalkan AK, Cakmak HA, Erturk M, Kalkan KE, Uzun F, Tasbulak O, Diker VO, Aydin S, Celik A.

Arq Bras Cardiol. 2018 Jul;111(1):39-47. doi: 10.5935/abc.20180109. Epub 2018 Jul 2. English, Portuguese.

Supplemental Content

Loading ...
Support Center